Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Altimmune ( (ALT) ) has issued an update.
On December 19, 2025, Altimmune reported positive 48-week topline results from its IMPACT Phase 2b trial of pemvidutide in patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, showing statistically significant improvements versus placebo in key non‑invasive markers of fibrosis and liver health, including Enhanced Liver Fibrosis scores, Liver Stiffness Measurement, liver fat content, ALT and cT1, alongside meaningful weight loss of up to 7.5% with the 1.8 mg dose and a favorable tolerability profile with very low treatment-related discontinuations and no serious treatment-related adverse events. Earlier in December 2025 the company also held an End-of-Phase 2 meeting with the FDA that produced alignment on parameters for a registrational Phase 3 trial in MASH patients with moderate to advanced fibrosis and potential integration of the FDA-qualified AIM-MASH AI Assist pathology tool, while Altimmune continued to tap its at-the-market equity program, raising approximately $54.6 million since September 30, 2025 to support ongoing development and positioning pemvidutide as a differentiated contender in the increasingly competitive MASH treatment landscape.
The most recent analyst rating on (ALT) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily influenced by its financial challenges, with severe profitability issues and cash flow difficulties. However, the positive sentiment from the earnings call and technical indicators showing bullish momentum provide some optimism. The valuation remains weak due to negative earnings and no dividend yield.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc., based in Gaithersburg, Maryland, is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a novel peptide that acts as a balanced 1:1 dual agonist of glucagon and GLP-1 receptors and is being developed for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), with pemvidutide holding FDA Fast Track designations for MASH and AUD.
Average Trading Volume: 3,125,691
Technical Sentiment Signal: Hold
Current Market Cap: $531.1M
For detailed information about ALT stock, go to TipRanks’ Stock Analysis page.